Page 48 - SaxoCell Annual Report 2021

MSC-PreStiGe

The MSC-PreStiGe project exploits the immunomodulatory potential of mesenchymal stromal
cells (MSC) extracted from umbilical cord tissue. This juvenile MSC population is particularly
characterized by an immense expansion potential, which allows the treatment of up to 25
patients with only one cell product. A first indication to be tested for the use of this preparation
will be severe acute graft-versus-host disease (GvHD) after allogeneic stem cell transplantation.
MSCs are considered to be highly potent drug candidates for many inflammation-associated
diseases for which there are currently no satisfactory therapies and which are associated with
SaxoCell Projects high mortality or high long-term morbidity.

The MSC application opportunities are based on the results of 20 years of worldwide research
with over 80,000 publications. Until now, this drug substance cannot be produced industrially in
large quantities with a clearly defined quality under pharmaceutical conditions at low cost.

In the project, an industrial value chain for the MSC drug substance Desacell® is being
developed and established in Saxony. As a result, MSCs will be available in the SaxoCell cluster in
large quantities in GMP quality under pharmaceutical conditions. Therefore, allogeneic MSCs
with high therapeutic potential will be available off-the shelf at reasonable costs that can be
applied easily and quickly.

Project Manager: Prof. Dr. Mario Rüdiger

Project Partners: Technical University Dresden, University Hospital Dresden, DKMS Stem Cell
Bank gGmbH, MDTB Cells GmbH

43